Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults

Overview of attention for article published in Expert Review of Clinical Immunology, February 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 898)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (92nd percentile)

So far, Altmetric has seen 2 news stories from 2 outlets.

Significant biosimilar activities this week include: 22 February 2023 | EU | AbbVie sued by Dutch group over Humira® pricing…

Pharmacokinetic similarity, including immunogenicity and safety profiles, was observed in the tocilizumab biosimilar, MSB11456…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.